Pipeline

Pipeline

Our Pipeline

Transthyretin amyloidosis (ATTR)

Pre-clinical
Phase 1
Phase 2
Phase 3
Registration

AKCEA-TTR-LRx

ATTR Amyloidosis (ATTR)

Pre-clinical

Cardiometabolic lipid disorders

Pre-clinical
Phase 1
Phase 2
Phase 3
Registration

Volanesorsen

Familial Chylomicronemia Syndrome (FCS)

Registration

Familial Partial Lipodystrophy (FPL)

Phase 3

AKCEA-APO(a)-LRx

Hyperlipoproteinemia(a) with CV Risk

Phase 2

AKCEA-ANGPTL3-LRx

Rare hyperlipidemias

Phase 2

NAFLD with Metabolic Complications

Phase 1

AKCEA-APOCIII-LRx

Hypertriglyceridemia with CV risk

Phase 2

The products listed on this page have not been approved.

Vision & mission

Learn about Akcea’s core values and hear from Akcea Canada’s Vice President & GM, Jared Rhines.

Clinical trials

Learn more about our ongoing research and development.